论文部分内容阅读
目的观察醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效及安全性。方法 68例急性脑出血患者随机分为对照组34例与试验组34例,2组均给予常规治疗以及对症治疗。对照组给予阿托伐他汀钙胶囊20 mg,每日1次,口服,试验组在对照组的基础上给予醒脑静注射液20 m L,每日2次,静脉滴注。2组均治疗21 d。比较2组患者的临床疗效、治疗前后血清C反应蛋白(CRP)、白细胞介素-1β(IL~(-1)β)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平及药物不良反应发生情况。结果治疗后,对照组临床总有效率为76.47%(26/34例),试验组为94.12%(32/34例,P<0.05)。治疗后,试验组和对照组血清CRP分别为(3.72±0.86),(5.18±0.51)mg·L~(-1),IL~(-1)β分别为(4.02±0.41),(5.48±0.58)ng·L~(-1),TNF-α分别为(19.47±2.13),(29.59±3.04)μg·L~(-1),NO分别为(3.03±0.34),(4.11±0.42)ng·L~(-1),MDA分别为(6.04±0.61),(7.17±0.76)μmol·m L~(-1),SOD分别为(162.01±16.34),(142.63±14.64)U·m L~(-1)(P<0.05)。试验组药物不良反应有头痛、恶心、皮疹,药物不良反应发生率为8.82%(3/34例),对照组药物不良反应有头痛、视物模糊、恶心、失眠,药物不良反应发生率为14.70%(5/34例,P>0.05)。结论醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效显著,安全性高。
Objective To observe the clinical efficacy and safety of xingnaojing injection combined with atorvastatin calcium capsule in the treatment of acute cerebral hemorrhage. Methods Sixty-eight patients with acute cerebral hemorrhage were randomly divided into control group (34 cases) and experimental group (34 cases). Both groups were given routine treatment and symptomatic treatment. Control group was given atorvastatin calcium capsule 20 mg once daily orally, and the experimental group was given Xinnaojing injection 20 ml on the basis of the control group, twice a day for intravenous drip. Both groups were treated for 21 days. The clinical curative effect was compared between the two groups. Serum C-reactive protein (CRP), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF- , Malondialdehyde (MDA) and superoxide dismutase (SOD) levels and adverse drug reactions. Results After treatment, the total effective rate of the control group was 76.47% (26/34 cases), the experimental group was 94.12% (32/34 cases, P <0.05). After treatment, the serum levels of CRP in the experimental and control groups were (3.72 ± 0.86) and (5.18 ± 0.51) mg · L -1, respectively. The levels of IL -1 β were (4.02 ± 0.41) and (5.48 ± 0.59) ng · L -1, and TNF-α were (19.47 ± 2.13) and (29.59 ± 3.04) μg · L -1, respectively, and those in NO were (3.03 ± 0.34) and (4.11 ± 0.42) ng · L -1 and MDA were (6.04 ± 0.61) and (7.17 ± 0.76) μmol · m L -1, and SOD were (162.01 ± 16.34) and (142.63 ± 14.64) U · m L ~ (-1) (P <0.05). Adverse drug reactions in the experimental group were headache, nausea, rash and adverse drug reactions rate was 8.82% (3/34 cases), the control group had adverse drug reactions headache, blurred vision, nausea, insomnia, the incidence of adverse drug reactions was 14.70 % (5/34 cases, P> 0.05). Conclusion Xingnaojing injection combined with atorvastatin calcium capsule in the treatment of acute cerebral hemorrhage has obvious curative effect and high safety.